Daniel S. Collins
Examiner (ID: 12325, Phone: (313)446-6535 , Office: P/3745 )
Most Active Art Unit | 3745 |
Art Unit(s) | 3745 |
Total Applications | 784 |
Issued Applications | 636 |
Pending Applications | 63 |
Abandoned Applications | 85 |
Applications
Application number | Title of the application | Filing Date | Status |
---|---|---|---|
Array
(
[id] => 17657509
[patent_doc_number] => 20220177974
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-06-09
[patent_title] => GENETIC SIGNATURES TO PREDICT PROSTATE CANCER METASTASIS AND IDENTIFY TUMOR AGGRESSIVENESS
[patent_app_type] => utility
[patent_app_number] => 17/390674
[patent_app_country] => US
[patent_app_date] => 2021-07-30
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 35656
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -9
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17390674
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/390674 | GENETIC SIGNATURES TO PREDICT PROSTATE CANCER METASTASIS AND IDENTIFY TUMOR AGGRESSIVENESS | Jul 29, 2021 | Pending |
Array
(
[id] => 17228984
[patent_doc_number] => 20210355540
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-11-18
[patent_title] => ASSESSMENT OF RISK OF ANEUPLOIDY
[patent_app_type] => utility
[patent_app_number] => 17/390620
[patent_app_country] => US
[patent_app_date] => 2021-07-30
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 13009
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17390620
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/390620 | ASSESSMENT OF RISK OF ANEUPLOIDY | Jul 29, 2021 | Abandoned |
Array
(
[id] => 17688237
[patent_doc_number] => 20220195529
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-06-23
[patent_title] => ISOFORMS OF GATA6 AND NKX2-1 AS MARKERS FOR DIAGNOSIS AND THERAPY OF CANCER AND AS TARGETS FOR ANTI-CANCER THERAPY
[patent_app_type] => utility
[patent_app_number] => 17/386088
[patent_app_country] => US
[patent_app_date] => 2021-07-27
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 57469
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -26
[patent_words_short_claim] => 198
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17386088
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/386088 | ISOFORMS OF GATA6 AND NKX2-1 AS MARKERS FOR DIAGNOSIS AND THERAPY OF CANCER AND AS TARGETS FOR ANTI-CANCER THERAPY | Jul 26, 2021 | Abandoned |
Array
(
[id] => 17414412
[patent_doc_number] => 20220049316
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-02-17
[patent_title] => METHOD FOR THE DIAGNOSIS, PROGNOSIS AND TREATMENT OF BREAST CANCER METASTASIS
[patent_app_type] => utility
[patent_app_number] => 17/385568
[patent_app_country] => US
[patent_app_date] => 2021-07-26
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 20045
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17385568
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/385568 | METHOD FOR THE DIAGNOSIS, PROGNOSIS AND TREATMENT OF BREAST CANCER METASTASIS | Jul 25, 2021 | Pending |
Array
(
[id] => 17214892
[patent_doc_number] => 20210348229
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-11-11
[patent_title] => COMBINATORIAL DNA SCREENING
[patent_app_type] => utility
[patent_app_number] => 17/383273
[patent_app_country] => US
[patent_app_date] => 2021-07-22
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 26485
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -27
[patent_words_short_claim] => 159
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17383273
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/383273 | Combinatorial DNA screening | Jul 21, 2021 | Issued |
Array
(
[id] => 17357168
[patent_doc_number] => 20220017964
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-01-20
[patent_title] => Cornulin (CRNN) Variants And Uses Thereof
[patent_app_type] => utility
[patent_app_number] => 17/378900
[patent_app_country] => US
[patent_app_date] => 2021-07-19
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 32818
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -24
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17378900
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/378900 | Cornulin (CRNN) Variants And Uses Thereof | Jul 18, 2021 | Abandoned |
Array
(
[id] => 17170811
[patent_doc_number] => 20210324481
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-10-21
[patent_title] => Crenolanib for Treating FLT3 Mutated Proliferative Disorders Associated Mutations
[patent_app_type] => utility
[patent_app_number] => 17/355468
[patent_app_country] => US
[patent_app_date] => 2021-06-23
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 14076
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -38
[patent_words_short_claim] => 41
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17355468
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/355468 | Crenolanib for Treating FLT3 Mutated Proliferative Disorders Associated Mutations | Jun 22, 2021 | Pending |
Array
(
[id] => 18948383
[patent_doc_number] => 11891667
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2024-02-06
[patent_title] => IGF2BP3 functional alterations and overexpression as a marker for cancer diagnosis and therapeutic response to IGF1R inhibitors
[patent_app_type] => utility
[patent_app_number] => 17/346540
[patent_app_country] => US
[patent_app_date] => 2021-06-14
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 10
[patent_figures_cnt] => 10
[patent_no_of_words] => 7176
[patent_no_of_claims] => 10
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 136
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17346540
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/346540 | IGF2BP3 functional alterations and overexpression as a marker for cancer diagnosis and therapeutic response to IGF1R inhibitors | Jun 13, 2021 | Issued |
Array
(
[id] => 17505563
[patent_doc_number] => 20220098665
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-03-31
[patent_title] => METHODS FOR PREDICTING ACUTE SEVERE COLITIS TREATMENT RESPONSE
[patent_app_type] => utility
[patent_app_number] => 17/340534
[patent_app_country] => US
[patent_app_date] => 2021-06-07
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 14392
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -2
[patent_words_short_claim] => 108
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17340534
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/340534 | METHODS FOR PREDICTING ACUTE SEVERE COLITIS TREATMENT RESPONSE | Jun 6, 2021 | Abandoned |
Array
(
[id] => 17097267
[patent_doc_number] => 20210285058
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-09-16
[patent_title] => Method for Assessing a Prognosis and Predicting a Response of Patients With Malignant Diseases to Immunotherapy
[patent_app_type] => utility
[patent_app_number] => 17/330817
[patent_app_country] => US
[patent_app_date] => 2021-05-26
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 30133
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -13
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17330817
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/330817 | Method for assessing a prognosis and predicting a response of patients with malignant diseases to immunotherapy | May 25, 2021 | Issued |
Array
(
[id] => 17200536
[patent_doc_number] => 20210340631
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-11-04
[patent_title] => METHODS FOR SUBTYPING OF LUNG SQUAMOUS CELL CARCINOMA
[patent_app_type] => utility
[patent_app_number] => 17/323429
[patent_app_country] => US
[patent_app_date] => 2021-05-18
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 36323
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17323429
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/323429 | METHODS FOR SUBTYPING OF LUNG SQUAMOUS CELL CARCINOMA | May 17, 2021 | Pending |
Array
(
[id] => 18376343
[patent_doc_number] => 20230151427
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-05-18
[patent_title] => COMBINATIONS OF MOLECULAR MARKERS WITH IMPROVED SENSITIVITY AND SPECIFICITY FOR PREDICTING AND TREATING PROSTATE CANCER
[patent_app_type] => utility
[patent_app_number] => 17/319705
[patent_app_country] => US
[patent_app_date] => 2021-05-13
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 10440
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 24
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17319705
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/319705 | COMBINATIONS OF MOLECULAR MARKERS WITH IMPROVED SENSITIVITY AND SPECIFICITY FOR PREDICTING AND TREATING PROSTATE CANCER | May 12, 2021 | Abandoned |
Array
(
[id] => 17444228
[patent_doc_number] => 20220064733
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-03-03
[patent_title] => PERSONALIZED ctDNA DISEASE MONITORING VIA REPRESENTATIVE DNA SEQUENCING
[patent_app_type] => utility
[patent_app_number] => 17/314958
[patent_app_country] => US
[patent_app_date] => 2021-05-07
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 19095
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -20
[patent_words_short_claim] => 55
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17314958
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/314958 | PERSONALIZED ctDNA DISEASE MONITORING VIA REPRESENTATIVE DNA SEQUENCING | May 6, 2021 | Pending |
Array
(
[id] => 17314965
[patent_doc_number] => 20210404013
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-12-30
[patent_title] => METHOD FOR IDENTIFYING A MEDICAL CONDITION IN A SUBJECT
[patent_app_type] => utility
[patent_app_number] => 17/314442
[patent_app_country] => US
[patent_app_date] => 2021-05-07
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 22683
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -21
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17314442
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/314442 | METHOD FOR IDENTIFYING A MEDICAL CONDITION IN A SUBJECT | May 6, 2021 | Pending |
Array
(
[id] => 17299994
[patent_doc_number] => 20210395833
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-12-23
[patent_title] => METHODS OF IDENTIFYING RISK OF BEVACIZUMAB-INDUCED PROTEINURIA AND HYPERTENSION
[patent_app_type] => utility
[patent_app_number] => 17/313742
[patent_app_country] => US
[patent_app_date] => 2021-05-06
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 40310
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17313742
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/313742 | METHODS OF IDENTIFYING RISK OF BEVACIZUMAB-INDUCED PROTEINURIA AND HYPERTENSION | May 5, 2021 | Abandoned |
Array
(
[id] => 17299984
[patent_doc_number] => 20210395823
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-12-23
[patent_title] => GENETIC MARKERS ASSOCIATED WITH ASD AND OTHER CHILDHOOD DEVELOPMENTAL DELAY DISORDERS
[patent_app_type] => utility
[patent_app_number] => 17/307793
[patent_app_country] => US
[patent_app_date] => 2021-05-04
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 29509
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -20
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17307793
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/307793 | GENETIC MARKERS ASSOCIATED WITH ASD AND OTHER CHILDHOOD DEVELOPMENTAL DELAY DISORDERS | May 3, 2021 | Abandoned |
Array
(
[id] => 17227153
[patent_doc_number] => 20210353709
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-11-18
[patent_title] => Proprotein Convertase Subtilisin/Kexin Type 1 (PCSK1) Variants And Uses Thereof
[patent_app_type] => utility
[patent_app_number] => 17/306699
[patent_app_country] => US
[patent_app_date] => 2021-05-03
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 19427
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17306699
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/306699 | Proprotein convertase subtilisin/kexin type 1 (PCSK1) variants and uses thereof | May 2, 2021 | Issued |
Array
(
[id] => 17037226
[patent_doc_number] => 20210254184
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-08-19
[patent_title] => ASSAY FOR THE DIAGNOSIS OF DERMATOPHYTOSIS
[patent_app_type] => utility
[patent_app_number] => 17/246920
[patent_app_country] => US
[patent_app_date] => 2021-05-03
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 12823
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -14
[patent_words_short_claim] => 28
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17246920
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/246920 | ASSAY FOR THE DIAGNOSIS OF DERMATOPHYTOSIS | May 2, 2021 | Abandoned |
Array
(
[id] => 17035022
[patent_doc_number] => 20210251980
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-08-19
[patent_title] => CRENOLANIB FOR TREATING FLT3 MUTATED PROLIFERATIVE DISORDERS ASSOCIATED MUTATIONS
[patent_app_type] => utility
[patent_app_number] => 17/234250
[patent_app_country] => US
[patent_app_date] => 2021-04-19
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 18911
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -32
[patent_words_short_claim] => 123
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17234250
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/234250 | CRENOLANIB FOR TREATING FLT3 MUTATED PROLIFERATIVE DISORDERS ASSOCIATED MUTATIONS | Apr 18, 2021 | Pending |
Array
(
[id] => 18146840
[patent_doc_number] => 20230020697
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-01-19
[patent_title] => METHODS AND COMPOSITIONS FOR DIAGNOSING, PROGNOSING, AND TREATING NEUROLOGICAL CONDITIONS
[patent_app_type] => utility
[patent_app_number] => 17/228440
[patent_app_country] => US
[patent_app_date] => 2021-04-12
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 132392
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17228440
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/228440 | Methods for diagnosing, prognosing, and treating parkinson's disease or parkinsonism | Apr 11, 2021 | Issued |